Selected immunological changes in patients with Goeckerman's therapy TNF-alpha, sE-selectin, sP-selectin, sICAM-1 and IL-8

Physiological Research

Volumn 55, Issue 6, 2006, Pages 699-706

  Borska L ^a   Fiala, Z ^a   Krejsek, J ^b   Andrys C ^b   Vokurkova D ^b   Hamakova K ^b   Kremlacek J ^a   Ettler, K ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

Author keywords

Goeckerman's therapy; IL 8; Psoriasis; sE selectin; sICAM 1; sP selectin; TNF alpha

Indexed keywords

COAL TAR; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; PADGEM PROTEIN; POLYCYCLIC AROMATIC HYDROCARBON; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; HUMAN; IMMUNOLOGICAL PARAMETERS; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS; PSORIASIS; SCORING SYSTEM; ULTRAVIOLET RADIATION;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; CELL ADHESION MOLECULES; COAL TAR; CYTOKINES; E-SELECTIN; FEMALE; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-8; KERATOLYTIC AGENTS; MALE; MIDDLE AGED; P-SELECTIN; PSORIASIS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; ULTRAVIOLET THERAPY;

EID: 33748772343     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. ABANMI A, AL HARTHI F, AL AGLA R, KHAN HA, TARIQ M: Serum levels of proinflammatory cytokines in psoriasis patients from Saudi Arabia. Int J Dermatol 44: 82-83, 2005.
2. AMEGLIO F, BONIFATI C, CARDUCCI M, ALEMANNO L, SACERDOTI G, FAZIO M: Soluble intercellular adhesion molecule-1 and procollagen III peptide are reliable markers of disease severity in psoriasis. Acta Derm Venereol (Stockh) Suppl 186: 19-20, 1994.
3. ANDRÝS C, KREJSEK J, SLEZÁK R, DRAHOŠOVÁ M, KOPECKÝ O: Serum soluble adhesion molecules (sICAM-1, sVCAM-1 and sE-selectin) and neopterin in patients with Sjögren's syndrome. Acta Med (Hradec Králové) 42: 97-101, 1999.
4. ANDRÝS C, POZLER O, KREJSEK J, DERNER V, DRAHOŠOVÁ M, KOPECKÝ O: Serum soluble adhesion molecules (sICAM-1, sVCAM-1 and sE-selectin) in healthy school aged children and adults. Acta Med (Hradec Králové) 43: 103-106, 2000.
5. BARKER JN: Adhesion molecules in cutaneous inflammation. Ciba Found Symp 189: 91-101, 101-106, 1995.
6. BONIFATI C, AMEGLIO F: Cytokines in psoriasis. Int J Dermatol 38: 241-251, 1999.
7. BONIFATI C, TRENTO E, CARDUCCI M, SACERDOTI G, MUSSI A, FAZIO M, AMEGLIO F: Soluble E-selectin and soluble tumour necrosis factor receptor (60 kD) serum levels in patients with psoriasis. Dermatology 190: 128-131, 1995.
8. BORSKÁ L, FIALA Z, ŠMEJKALOVÁ J, HAMÁKOVÁ K, KREMLÁČEK J: Possible genotoxic risk of combined exposure to pharmaceutical coal tar and UV-B radiation. Cent Eur J Public Health Suppl 12: 14-15, 2004.
9. BORSKÁ L, FIALA Z, KREJSEK J, HAMÁKOVÁ K, ANDRÝS C, ŠMEJKALOVÁ J, VOKURKOVÁ D, KREMLÁČEK J: Cytogenetic and immunological changes after dermal exposure to polycyclic aromatic hydrocarbons and UV radiation. Physiol Res 55: 317-323, 2006.
10. CASTRANOVA V, MA JY, YANG HM, ANTONINI JM, BUTTERWORTH L, BARGER MW, ROBERTS J, MA JK: Effect of exposure to diesel exhaust particles on the susceptibility of the lung to infection. Environ Health Perspect 109: 609-612, 2001.
11. CZECH W, SCHOPF E, KAPP A: Soluble E-selectin in sera of patients with atopic dermatitis and psoriasis correlation with disease activity. Br J Dermatol 134: 17-21, 1996.
12. D'AURIA L, BONIFATI C, MUSSI A, AMEGLIO F: Monitoring of sE-selectin levels in three different dermatoses. Clin Ter 149: 49-52, 1998.
13. DE RIE MA, GOEDKOOP AY, BOS JD.: Overview of psoriasis. Dermatol Ther 17: 341-349, 2004.
14. DUAN H, KOGA T, KOHDA F, HARA H, URABE K, FURUE M: Interleukin-8-positive neutrophils in psoriasis. J Dermatol Sci 26: 119-124, 2001.
15. ETTEHADI P, GREAVES MW, WALLACH D, ADERKA D, CAMP RD: Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol 96: 146-151, 1994.
16. FAHY O, TSICOPOULOS A, HAMMAD H, PESTEL J, TONNEL AB, WALLAERT B: Effects of diesel organic extracts on chemokine production by peripheral blood mononuclear cells. J Allergy Clin Immunol 103: 1115-1124, 1999.
17. FAHY O, HAMMAD H, SENECHAL S, PESTEL J, TONNEL AB, WALLAERT B, TSICOPOULOS A: Synergistic effect of diesel organic extracts and allergen Der p 1 on the release of chemokines by peripheral blood mononuclear cells from allergic subjects: involvement of the MAP kinase pathway. Am J Respir Cell Mol Biol 23: 247-254, 2000.
18. FIALA Z, BORSKÁ L, VYSKOČIL A, MAŠÍN V, SRB V: Polycyclic aromatic hydrocarbons II. Toxic effects. (in Czech) Acta Med (Hradec Králové) Suppl 43: 37-61, 2000.
19. FIALA Z, BORSKÁ L, HAMÁKOVÁ K, ANDRÝS C, ŠMEJKALOVÁ J, VOKURKOVÁ D, KREMLÁČEK J: Biochemical, immunological and cytogenetical changes after dermal exposure to polycyclic aromatic hydrocarbons and UV-B radiation. Toxicol Appl Pharmacol 197: 185, 2004.
20. GARDOŠOVÁ D, MEZENCEVOVÁ V, KALINA I, HEJJ F, KOPKA M, PETROVIČOVÁ J: Mutagenic effects of pharmaceutical coal tar in psoriatic patients. (in Slovak) Bratisl Lék Listy 98: 146-149, 1997.
21. GROVES RW, ALLEN MH, ROSS EL, BARKER JN, MACDONALD DM: Tumour necrosis factor alpha is proinflammatory in normal human skin and modulates cutaneous adhesion molecule expression. Br J Dermatol 132: 345-352, 1995.
22. JACOB SE, NASSIRI M, KERDEL FA, VINCEK V: Simultaneous measurement of multiple Th1 and Th2 serum cytokines in psoriasis and correlation with disease severity. Mediators Inflamm 12: 309-313, 2003.
23. JENNER N, CAMPBELL J, PLUNKETT A, MARKS R: Cost of psoriasis: A study on the morbidity and financial effects of having psoriasis in Australia. Australas J Dermatol 43: 255-261, 2002.
24. KONSTANTINOVA NV, DUONG DM, REMENYIK E, HAZARIKA P, CHUANG A, DUVIC M: Interleukin-8 is induced in skin equivalents and is highest in those derived from psoriatic fibroblasts. J Invest Dermatol 107: 615-621, 1996.
25. KOWALZICK L, BILDAU H, NEUBER K, KOHLER I, RING J: Clinical improvement in psoriasis during dithranol/UVB therapy does not correspond with a decrease in elevated serum soluble ICAM-1 levels. Arch Dermatol Res 285: 233-235, 1993.
26. KREJSEK J, KOPECKÝ O: Clinic immunology. (in Czech) Nucleus, Hradec Králové, 2004, 985 p.
27. KUNDAKCI N, OSKAY T, ÖLMEZ Ü, TUTKAK H, GURGEY E: Association of psoriasis vulgaris with HLA class I and class II antigens in the Turkish population, according to the age at onset. Int J Dermatol 41: 345-348, 2002.
28. LEBWOHL M, ALI S: Treatment of psoriasis. Part 1. Topical therapy and phototherapy. J Am Acad Dermatol 45: 487-498, 2001.
29. LECUREUR V, FERREC EL, N'DIAYE M, VEE ML, GARDYN C, GILOT D, FARDEL O: ERK-dependent induction of TNF-alpha expression by the environmental contaminant benzo(a)pyrene in primary human macrophages. FEBS Lett 579: 1904-1910, 2005.
30. LEE ML, TO T, NICHOLSON E, SCHRIEBER L: Endothelial cell adhesion molecules in psoriasis. Australas J Dermatol 35: 65-70, 1994.
31. LEGRET M, ODIE L, DEMARE D, JULLIEN A: Leaching of heavy metals and polycyclic aromatic hydrocarbons from reclaimed asphalt pavement. Water Res 39: 3675-3685, 2005.
32. LÜLLMANN H, MOHR K, WEHLING M: Pharmakologie und Toxikologie. Georg Thieme Verlag, Stuttgart, 1999.
33. LUSTER MI, ROSENTHAL GJ: Chemical agents and immune response. Environ Health Perspect 101: 219-226, 1993.
34. MA JY, RENGASAMY A, FRAZER D, BARGER MW, HUBBS AF, BATTELI L, TOMBLYN S, STONE S, CASTRANOVA V: Inhalation exposure of rats to asphalt fumes generated at paving temperatures alters pulmonary xenobiotic metabolism pathway without lung injury. Environ Health Perspect 111: 1215-21, 2003.
35. MORROW T: The "Heartbreak of Psoriasis" Has MET ITS MATCH! Manag Care 12: 17-18, 2003.
36. MUSSI A, BONIFATI C, CARDUCCI M, D'AGOSTO G, PIMPINELLI F, D'URSO D, D'AURIA L, FAZIO M, AMEGLIO F: Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. Biol Regul Homeost Agents 11: 115-118, 1997.
37. NOVOTNY F: Psoriasis. Actual views. (in Czech) Grada, Prague, 2002, 144 p.
38. OZAWA M, AIBA S: Immunopathogenesis of psoriasis. Curr Drug Targets Inflamm Allergy 3: 137-144, 2004.
39. PARKIN J, COHEN B: An overview of the immune system. Lancet 357: 1777-1789, 2001.
40. PIETRUCZUK M, PIETRUCZUK A, PANCEWICZ S, HERMANOWSKA-SZPAKOWICZ T: ICAM-1: structure, biological role and clinical significance. Pol Merkuriusz Lek 17: 507-511, 2004.
41. PRINZ JC: Psoriasis vulgaris - a sterile antibacterial skin reaction mediated by cross-reactive T cells? An immunological view of the pathophysiology of psoriasis. Clin Exp Dermatol 26: 326-332, 2001.
42. ROTHLEIN R, MAINOLFI EA, CZAJKOWSKI M, MARLIN SD: A form of circulating ICAM-1 in human serum. J Immunol 147: 3788-3793, 1991.
43. SCOTT RAW, NEIL HS: Psoriasis and the new biological agents: interrupting a T-AP dance. CMAJ 170: 1933-1941, 2004.
44. SCHOPF RE, NAUMANN S, REHDER M, MORSCHES B: Soluble intercellular adhesion molecule-1 levels in patients with psoriasis. Br J Dermatol 128: 34-7, 1993.
45. STENFORS N, NORDENHALL C, SALVI SS, MUDWAY I, SODERBERG M, BLOMBERG A, HELLEDAY R, LEVIN JO, HOLGATE ST, KELLY FJ, FREW AJ, SANDSTROM T: Different airway inflammatory response in asthmatic and healthy humans exposed to diesel. Eur Respir J 23: 82-86, 2004.
46. SVOZIL M: Immunopathogenesis of psoriasis and its current therapy. (in Czech) Ceska Slov Farm 51: 213-19, 2002.
47. SZEPIETOWSKI J, WASIK F, BIELICKA E, NOCKOWSKI P, NOWOROLSKA A: Soluble E-selectin serum levels correlate with disease activity in psoriatic patients. Clin Exp Dermatol 24: 33-36, 1999.
48. ŠTORK J, KLUBAL R: Imunopatogenesis of psoriasis. (in Czech) Česka Slov Derm 76: 311-317, 2001.
49. TERAJIMA S, HIGAKI M, IGARASHI Y, NOGITA T, KAWASHIMA M: An important role of tumor necrosis factor-alpha in the induction of adhesion molecules in psoriasis. Arch Dermatol Res 290: 246-52, 1998.
50. THAMI GP, SARKAR R: Coal tar: past, present and future. Clin Exp Dermatol 27: 99-103, 2002.
51. TIGALONOVA M, BJERKE JR, GALLATI H, DEGRE M, JABLONSKA S, MAJEWSKI S, MATRE R: Serum levels of interferons and TNF-alpha are not correlated to psoriasis activity and therapy. Acta Derm Venereol (Stockh) Suppl 186: 25-27, 1994.
52. VAŠKŮ V: Some etiopathogenetic aspects of psoriasis. Postgraduální Medicína 6: 323-325, 2004. (in Czech).
53. VICTOR FC, GOTTLIEB AB: TNF-alpha and apoptosis: implications for the pathogenesis and treatment of psoriasis. J Drugs Dermatol 1: 264-275, 2002.
54. ZHANG M, ZHANG YZ, WANG S, WANG L, LI FY: Dendritic cells, natural killer cells and adhesion molecules in psoriasis. Sichuan Da Xue Xue Bao Yi Xue Ban 35: 626-629, 2004.